Breaking News

Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

Care Access to provide decentralized, mobile research site operations for AstraZeneca’s AZD7442 Phase III trial in the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Care Access Research, a decentralized research organization (DRO) that connects physicians and research experts, entered a collaboration with AstraZeneca to accelerate a clinical trial in the U.S. for AZD7442, AstraZeneca’s long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19.   Care Access is supporting the Phase III trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and pre-emptive treatment in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters